about
Demystified...adhesion molecule deficiencies.Expression and targeting of lymphocyte function-associated antigen 1 (LFA-1) on white blood cells for treatment of allergic asthma.Gangliosides block Aggregatibacter Actinomycetemcomitans leukotoxin (LtxA)-mediated hemolysisLFA-1-targeting Leukotoxin (LtxA; Leukothera®) causes lymphoma tumor regression in a humanized mouse model and requires caspase-8 and Fas to kill malignant lymphocytesAdhesion between human neutrophils and immobilized endothelial ligand vascular cell adhesion molecule 1: divalent ion effects.Adhesion-activating phorbol ester increases the mobility of leukocyte integrin LFA-1 in cultured lymphocytes.Leukotoxin (Leukothera®) targets active leukocyte function antigen-1 (LFA-1) protein and triggers a lysosomal mediated cell death pathway.A mechanism for antibody-mediated outside-in activation of LFA-1.A functionally relevant conformational epitope on the CD9 tetraspanin depends on the association with activated beta1 integrin.Activation of the integrin alpha v beta 3 involves a discrete cation-binding site that regulates conformation.The activation state of the integrin alpha IIb beta 3 affects outside-in signals leading to cell spreading and focal adhesion kinase phosphorylation.The role of stromal cell heparan sulphate in regulating haemopoiesis.Leukocyte adhesion molecules.Ligand-dependent activation of integrin alpha vbeta 3.Inhibition of human eosinophil activation by a cysteinyl leukotriene receptor antagonist (pranlukast; ONO-1078).Time course of beta 2-integrin CD11b/CD18 (Mac-1, alpha M beta 2) upregulation on neutrophils and monocytes after coronary artery bypass grafting. CD11b upregulation after CABG surgery.
P2860
Q34158852-E3B3EAFE-284E-4E9D-AE7D-6DAA3FBF3337Q35115469-1BCCEF57-336F-436F-822D-486DA3A38353Q35155672-FB6193D3-64C5-4FD1-A638-AD3C80B3EA1BQ36006344-963A5F26-0AAD-42F3-8501-7A1C0BAC5A55Q37260250-B79A035D-663F-4492-9E7D-6A2E90EFC48EQ37354696-DEFF089B-3E5D-44F5-AB92-B3FFE31FCE1FQ39370760-6FDA6A48-A490-471C-86C1-6C3FEE4BD6CEQ40024433-840DA0F4-464E-4577-913D-E38FF716440BQ40692932-78B01A54-C61C-4AED-A9D3-F05507537381Q41238021-6508E01E-5664-47A4-8C69-82300808D2B1Q41323508-A6D2A0D9-9D67-4C90-A8F0-86ED0DE9EA9BQ41489325-9DADB574-3C9C-4886-B88B-2025AE8C556DQ41657045-A52D7F64-BEB3-48C2-A3A5-6FAA99C506C7Q44226106-003BA827-AED2-4D49-BDB6-560B243E1AF2Q44518361-894EBEF1-272A-4302-BF0C-305A7E770C72Q51580911-2B1183FE-3188-4518-B656-0802948AD98D
P2860
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Control of leukocyte integrin activation.
@en
type
label
Control of leukocyte integrin activation.
@en
prefLabel
Control of leukocyte integrin activation.
@en
P2093
P2860
P356
P1476
Control of leukocyte integrin activation.
@en
P2093
P2860
P356
10.1164/AJRCCM/148.6_PT_2.S55
P433
P577
1993-12-01T00:00:00Z